Retrospective study of Pembrolizumab monotherapy in patients with advanced non-small cell lung cancer
Latest Information Update: 06 Mar 2020
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2020 New trial record